Table 1 Characteristics of women with breast cancer diagnosed from 2013 to 2019.
From: Post-diagnosis weight trajectories and mortality among women with breast cancer
Characteristics | Overalla,b (N = 5441) |
|---|---|
Length of follow-up, years | 3.2 ± 1.8 (0.01–7.2) |
Number of weights | 34.4 ± 25.5 (2–310) |
Time from Dx to first weight measure, months | 0.8 ± 0.8 (0–6.0) |
Age at diagnosis, years | 61.0 ± 13.2 (22–100) |
Age at diagnosis, n | |
≤45 | 580 (10.7) |
45–55 | 1354 (24.9) |
55–70 | 2169 (39.9) |
≥70 | 1338 (24.6) |
BMI at diagnosis, kg/m2 | 29.3 ± 6.9 (14.2–74.3) |
BMI group at diagnosis | |
Underweight (≤18.5) | 67 (1.2) |
Normal (18.5–25) | 1565 (28.9) |
Overweight (25–30) | 1672 (30.7) |
Class I obesity (30–35) | 1127 (20.7) |
Class II obesity (≥35) | 1010 (18.6) |
Race and ethnicity | |
Non-Hispanic white | 4367 (80.3) |
Non-Hispanic Black | 488 (9.0) |
Hispanic | 359 (6.6) |
Other/unknown | 227 (4.2) |
Clinical stage at diagnosis | |
Stage I | 3465 (63.7) |
Stage II | 1325 (24.4) |
Stage III | 323 (5.9) |
Unknown | 328 (6.0) |
Tumor subtypec | |
ER/PR+, HER2− | 3725 (68.5) |
ER/PR+, HER2+ | 398 (7.3) |
ER/PR−, HER2+ | 188 (3.5) |
TNBC | 524 (9.6) |
Unknown | 606 (11.1) |
Chemotherapy | |
No | 3297 (60.6) |
Yes | 2144 (39.4) |
Radiation | |
No | 2019 (37.1) |
Yes | 3422 (62.9) |
Type of surgery | |
No surgery | 327 (6.0) |
Breast-conserving surgery | 3435 (63.1) |
Mastectomy | 1675 (30.8) |
Endocrine therapyd | |
No | 1131 (20.8) |
Yes | 4310 (79.2) |
Tamoxifene | |
No | 4502 (82.7) |
Yes | 939 (17.3) |
Aromatase inhibitore | |
No | 1679 (30.9) |
Yes | 3762 (69.1) |
